MedPlus Health Services Limited disclosed on July 26, 2026, that its subsidiary, Optival Health Solutions Private Limited, has received a suspension order for a drug license in Karnataka. The regulatory action affects a single store located at Busstand Road, Bijapur, and carries a quantifiable financial impact, with the company estimating a potential revenue loss of ₹0.29 lacs. This incident highlights operational compliance risks within the pharmacy chain’s network, although the limited duration and monetary value suggest contained immediate consequences.

The order was issued by the Assistant Director, Drugs Control Administration, Vijayapura Circle, Vijayapura, Karnataka. The authority cited violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. MedPlus received the communication on July 25, 2026, and subsequently filed the disclosure with the stock exchanges to comply with transparency norms.

Regulatory and Financial Details

The disclosure was made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It also references SEBI Master Circular No. HO/49/14/14(7)2025-CFD POD2/I/3762/2026 dated January 30, 2026. The specific details of the action are outlined below:

The Company Secretary and Compliance Officer, Shrenik Soni, signed the filing, confirming the information is available on the company’s website as well as those of the BSE and NSE. The brief two-day suspension indicates a procedural or minor compliance lapse rather than a systemic failure, given the low financial exposure.

What the Numbers Show

The estimated revenue loss of ₹0.29 lacs is negligible relative to the overall scale of MedPlus Health Services Limited’s operations, suggesting that this isolated incident will not materially affect the consolidated financial results. However, it underscores the importance of strict adherence to local drug control regulations across all franchise and owned stores. The specificity of the violation—Rule 65 of the Drugs and Cosmetics Act—typically relates to conditions of storage or sale, implying a need for targeted operational review at the affected location rather than a broad strategic overhaul.

MedPlus Health Services Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-26 to the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE). The filing, dated July 23, 2026, was signed by Company Secretary Shrenik Soni and complies with Regulation 34(2)(f) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The report outlines the company’s environmental, social, and governance (ESG) performance, including workforce data, sustainability practices, and corporate social responsibility (CSR) activities.

Operational Footprint and Workforce

MedPlus operates as one of India’s largest retail pharmacy chains, serving consumers across 14 states. Approximately 90% of its operations are conducted through its subsidiary, Optival Health Solutions Private Limited (OHSPL), which is included in the reporting boundary. The company maintains a network of 5,714 locations nationwide, comprising 5 national plants and 5,709 offices or outlets. There are no international operations, and export contribution stands at 0%.

As of the end of FY2026, MedPlus employed 27,686 permanent employees, with females constituting 31.76% of the workforce. The company reported no permanently employed workers or differently abled employees. Key workforce metrics are summarized below:

The median annual remuneration for directors was ₹10,50,000 for males and ₹10,00,000 for females. Key Managerial Personnel received a median annual remuneration of ₹73,02,562. The company provided health and accident insurance coverage to 100% of permanent employees. Maternity benefits covered 14.09% of total permanent employees (3,900 individuals), while day care facilities were available for 5,252 male and 2,764 female employees.

Environmental Stewardship and Governance

MedPlus has implemented several environmental initiatives, including the transition from single-use plastic bags to compostable bags in stores and the use of recyclable plastic bags and biodegradable covers in warehouses. The company is replacing lighting with energy-efficient alternatives and monitoring energy consumption across its network. Waste management involves recycling plastic and e-waste through third-party providers, while hazardous waste is managed by authorized specialists.

Governance policies aligned with all nine National Guidelines on Responsible Business Conduct (NGRBC) principles have been approved by the Board. These policies are reviewed annually for performance-related matters and quarterly for compliance-related matters. No external agency was engaged for independent assessment of these policies; oversight is maintained through internal audits and Board committee reviews. The company reported zero fines, penalties, or non-monetary sanctions during the year.

CSR and Stakeholder Engagement

During FY2026, MedPlus executed 15 CSR projects, all targeting vulnerable and marginalized groups. Notable initiatives included the Sir C.V. Raman Akshaya Science Centre (250 beneficiaries), Student Mobility Support Programme (97 beneficiaries), Solar Panels for farmers in Adilabad district (100 beneficiaries), and an Ambulance project (1,000 beneficiaries). The company engages with stakeholders—including patients, employees, suppliers, and regulators—through various channels such as retail interactions, social media, and shareholder meetings. A comprehensive materiality assessment involving all stakeholder groups was conducted to identify key ESG issues.

Financial Disclosures

The BRSR discloses the following standalone financial parameters for the reporting period:

The standalone turnover figure was referenced but not fully disclosed in the filing. The report emphasizes that product information disclosures covering environmental, social, and safe usage parameters are provided on 100% of products as a percentage of total turnover. No voluntary or forced product recalls, nor any data breaches, were reported during the period.